...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Endocrine Connections >Bromocriptine and insulin sensitivity in lean and obese subjects
【24h】

Bromocriptine and insulin sensitivity in lean and obese subjects

机译：肥胖和肥胖受试者的溴隐亭和胰岛素敏感性

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Bromocriptine is a glucose-lowering drug, which was shown to be effective in obese subjects with insulin resistance. It is usually administered in the morning. The exact working mechanism of bromocriptine still has to be elucidated. Therefore, in this open-label randomized prospective cross-over mechanistic study, we assessed whether the timing of bromocriptine administration (morning vs evening) results in different effects and whether these effects differ between lean and obese subjects. We studied the effect of bromocriptine on insulin sensitivity in 8 lean and 8 overweight subjects using an oral glucose tolerance test. The subjects used bromocriptine in randomized cross-over order for 2 weeks in the morning and 2 weeks in the evening. We found that in lean subjects, bromocriptine administration in the evening resulted in a significantly higher post-prandial insulin sensitivity as compared with the pre-exposure visit (glucose area under the curve (AUC) 742?mmol/L?*?120?min (695–818) vs 641 (504–750), P ?=?0.036, AUC for insulin did not change, P ?=?0.575). In obese subjects, both morning and evening administration of bromocriptine resulted in a significantly higher insulin sensitivity: morning administration in obese: insulin AUC (55,900?mmol/L?*?120?min (43,236–96,831) vs 36,448 (25,213–57,711), P ?=?0.012) and glucose AUC P ?=?0.069; evening administration in obese: glucose AUC (735?mmol/L?*?120?min (614–988) vs 644 (568–829), P ?=?0.017) and insulin AUC, P ?=?0.208. In conclusion, bromocriptine increases insulin sensitivity in both lean and obese subjects. In lean subjects, this effect only occurred when bromocriptine was administrated in the evening, whereas in the obese, insulin sensitivity increased independent of the timing of bromocriptine administration.
机译：溴隐亭是一种降低葡萄糖的药物，已被证明对具有胰岛素抵抗的肥胖受试者有效。通常在早晨服用。溴隐亭的确切工作机制仍需阐明。因此，在这项开放标签的随机前瞻性交叉机制研究中，我们评估了溴隐亭施用的时间（上午与晚上）是否会产生不同的效果，以及瘦和肥胖受试者之间这些效果是否不同。我们使用口服葡萄糖耐量试验研究了溴隐亭对8名瘦肉和8名超重受试者的胰岛素敏感性的影响。受试者在早晨2周和晚上2周以随机交叉顺序使用溴隐亭。我们发现在瘦弱的受试者中，与暴露前就诊相比，晚上服用溴隐亭会导致餐后胰岛素敏感性显着提高（曲线下葡萄糖面积（AUC）为742？mmol / L？*？120？min （695–818）对641（504–750），P == 0.036，胰岛素的AUC不变，P == 0.575）。在肥胖的受试者中，早晨和晚上服用溴隐亭会导致胰岛素敏感性显着提高：肥胖的早晨服用：胰岛素AUC（55,900？mmol / L？*？120？min（43,236–96,831）vs 36,448（25,213–57,711） ，P≤0.012）和葡萄糖AUCP≤0.069。肥胖者晚上服用：葡萄糖AUC（735？mmol / L？* 120？min（614–988）对644（568–829），P == 0.017）和胰岛素AUC，P == 0.208。总之，溴隐亭在肥胖和肥胖受试者中均可增加胰岛素敏感性。在瘦弱的受试者中，仅当晚上服用溴隐亭时才出现这种效果，而在肥胖人群中，胰岛素敏感性的提高与溴隐亭的施用时间无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号